

6:30 – 7:45 AM	REGISTRATION/BREAKFAST/EXHIBITS/POSTERS BALLROOM DE
7:45 – 8:00 AM	<p>Welcome & Announcements</p> <p>SESSION A CLASSIFICATION/EPIDEMIOLOGY/PROGNOSTIC FACTORS</p> <p><i>Primary Chair:</i> Joan Guitart, MD <i>Co-Chairs:</i> Jose Antonio Sanches Junior, MD, PhD; Laura Pincus, MD; Elise A. Olsen, MD</p>
8:00 – 8:20 AM	Overview & Updates in the Classification of Cutaneous Lymphomas <i>Joan Guitart, MD</i>
8:20 – 10:20 AM	<p>A-01 The Modified TNMB Staging Criteria Fail to Identify Sézary Syndrome Patients with Low Blood Burden <i>Lauren Chrisman, BA</i></p> <p>A-02 Clinical Consequences of Reclassifying Low-grade Malignant Cutaneous Lymphomas as Cutaneous Lymphoproliferative Disorders <i>Rein Willemze, MD</i></p> <p>A-03 Cutaneous Intravascular Lymphoproliferations: A Proposal for a Diagnostic Algorithm <i>Brandy Phan, BSA</i></p> <p>A-04 Racial Differences in the Skin Microbiome of Cutaneous T-Cell Lymphoma Patients <i>Yanzhen (Janet) Pang, BS</i></p> <p>A-05 The Impact of Lymph Node Clonality Status in the Prognosis of Mycosis Fungoides and Sézary Syndrome <i>Denis Miyashiro, MD, PhD</i></p> <p>A-06 The Role of Bone Marrow Biopsies in Diagnosis and Prognosis of Cutaneous T-Cell Lymphoma <i>Sima Rozati, MD, PhD</i></p> <p>A-07 Chronic Inflammatory Comorbidities in Primary Cutaneous Marginal Zone Lymphoma: Identifying the Underlying Cause <i>William Nguyen, BS</i></p> <p>A-08 Overlapping Diagnostic Criteria in Lymphomatoid Papulosis – A Prospective Multicenter Study On 141 Biopsy Specimens <i>Christina Mitteldorf, MD</i></p> <p>A-09 Prognostic Factors for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Multicenter Retrospective Study From Japan <i>Tomomitsu Miyagaki, MD, PhD</i></p> <p>A-10 Pediatric Cutaneous Lymphomas Including Rare Subtypes: A 40-Year Experience at a Tertiary Referral Center <i>Silvia Alberti-Violetti, MD, PhD</i></p> <p>A-11 Long Term Outcomes of Juvenile-onset Mycosis Fungoides <i>Rishabh Lohray, BS</i></p> <p>A-12 Clinical Characteristics and Outcomes of Hypopigmented Mycosis Fungoides: A Retrospective Multicenter Study <i>Jongbin Park, MD, PhD</i></p>
10:20 – 10:40 AM	REFRESHMENT BREAK/EXHIBITS/POSTERS
10:40 – 11:40 AM	<p><i>Primary Chair:</i> Emilio Berti, MD <i>Co-Chairs:</i> Christina Mitteldorf, MD; Kerri E. Rieger, MD, PhD</p> <p>A-13 Curing Advanced-Stage Mycosis Fungoides/ Sézary Syndrome <i>Seda Purnak, MD</i></p> <p>A-14 Patterns of Care in Cutaneous T-Cell Lymphoma: Outcome Analysis from the Lymphoma Epidemiology of Outcomes (LEO) Prospective Cohort Study <i>Pamela Blair Allen, MD, MSc</i></p> <p>A-15 Primary Cutaneous Lymphomas/Lymphoproliferative Disorders with T-Follicular Helper Phenotype: A Tertiary Cancer Center Experience <i>Ziba Rahbar, MD, MPH</i></p> <p>A-16 T-Follicular Helper Immunophenotype in Mycosis Fungoides and Sézary Syndrome: A Clinico-Pathological Analysis of 33 Cases <i>Emilio Berti, MD</i></p> <p>A-17 Reactive T- and B-Cell Rich Lymphoid Proliferations – Spectrum and Subtypes <i>Werner Kempf, MD</i></p>
11:40 AM – 12:10 PM	<p>Standardization of Clinical and Pathologic Reports of Mycosis Fungoides/Sézary Syndrome</p> <p><i>Primary Chair:</i> Emilia Hodak, MD</p> <p><i>Co-Chairs:</i> Alejandro A. Gru, MD; Youn H. Kim, MD; Larisa J. Geskin, MD; Werner Kempf, MD</p> <p><i>Emilia Hodak, MD (Clinical) & Alejandro A. Gru, MD (Pathology)</i></p>
12:10 – 12:45 PM	<p>Zackheim Lecture</p> <p>Building Human Peripheral T-Cell Lymphoma Models for Biological and Therapeutic Investigations <i>Wing C. (John) Chan, MD</i></p>
12:45 – 1:45 PM	LUNCH/EXHIBITS/POSTERS
1:45 – 2:45 PM	<p>POSTER/EXHIBIT RECEPTION</p> <p>SESSION C BIOLOGIC INSIGHTS</p> <p><i>Primary Chair:</i> Jaehyuk Choi, MD, PhD <i>Co-Chairs:</i> Sean Whittaker, MD; Michael Girardi, MD; Cornelis P. Tensen, PhD; Ivan V. Litvinov, MD, PhD</p>
2:45 – 3:05 PM	Genomic Characterization of Cutaneous Lymphomas <i>Jaehyuk Choi, MD, PhD</i>
3:05 – 5:05 PM	<p>C-01 Molecular Profiling Of Skin Lesions from a Patient with Angioimmunoblastic T-Cell Lymphoma in Comparison to Tumor-stage Mycosis Fungoides Reveals Disease-specific Markers <i>Emry Cohenour, MS</i></p> <p>C-02 Clinical-Pathologic Characterization of Gene-Fusion Positive Cutaneous T-Cell Lymphoma Cases <i>Liam Donnelly, MD</i></p> <p>C-03 Aberrant Serine Phosphorylation of STAT3 in Sézary Syndrome <i>Victoria Campbell, MSci, Mres</i></p> <p>C-04 Unraveling the Role of HDAC10 in the Molecular Background of Sézary Syndrome <i>Monika Pieniawska, MSc</i></p> <p>C-05 Tracing the Evolutionary Origins and Transcriptomic Variability in Sézary Syndrome and Mycosis Fungoides <i>Simon Cao, MPH</i></p> <p>C-06 Characterization of Genomic Changes in Large Cell Transformed Mycosis Fungoides and Sézary Syndrome <i>Jennifer Wang, MD</i></p> <p>C-07 Exploring the Role of Clonal T-LGL Proliferations in Cutaneous T-Cell Lymphoma <i>Yumeng (Julia) Zhang, MD</i></p> <p>C-08 MHC-I Upregulation Safeguards Neoplastic T Cells in the Skin Against NK Cell-mediated Eradication in Mycosis Fungoides <i>Yun-Tsan Chang, PhD</i></p> <p>C-09 Next Generation Sequencing of Subcutaneous Panniculitis-like T-Cell Lymphoma <i>Rebekah Wieland, MD, MS</i></p> <p>C-10 Bexarotene-induced Upregulation of Siglec-7 and Siglec-9 on Peripheral Blood T Cells: A Potential Therapeutic Target <i>Miki Kume, MD, PhD</i></p>
5:05 – 5:35 PM	<p>DEBATE: The Origin of Mycosis Fungoides: Blood vs Skin</p> <p><i>Moderator: Emmanuella Guenova, MD, PhD</i> <i>Robert Gniadecki, MD, PhD (Blood) & Michael Girardi, MD (Skin)</i></p>
5:35 PM	CLOSING REMARKS/ADJOURN DAY 1

SESSION B | CUTANEOUS LYMPHOMA INTERNATIONAL CONSORTIUM – PROCLIPI STUDIES**Primary Chair:** Julia Scarisbrick, MBChB, MD | **Co-Chairs:** Larisa J. Geskin, MD; Jade Cury-Martins, MD, PhD**Update on PROCLIPI International Efforts** | Julia Scarisbrick, MBChB, MD**Harnessing the Power of Machine Learning and AI for Collaborative Clinical-Pathological Genomic Integration: ISCL Initiative**

Larisa J. Geskin, MD

B-01 Identifying Patients at Risk of Disease Progression & Poorer Outcomes: Results from the PROCLIPI Study | Julia Scarisbrick, MBChB, MD**B-02 Response Rates, Response Duration, And TTNT In Advanced Stage Mycosis Fungoides/Sézary Syndrome Patients from the PROCLIPI Study**

Pietro Quaglino, MD

B-03 Prognostic Implications of Lesional Body Surface Area in Early-stage Mycosis Fungoides | Juliette Kersten, MD**HELINN LUNCH SATELLITE SYMPOSIUM | BALLROOM C****Perspectives in the Management of Stage IA/IB MF-CTCL: Current Concepts in Clinical Practice** | Oleg E. Akilov, MD, PhD**SESSION D | PATHOGENESIS/BIOMARKERS****Primary Chair:** Maarten Vermeer, MD, PhD | **Co-Chairs:** Jan Nicolay, MD, MSc; Tomomitsu Miyagaki, MD, PhD; Stefan M. Schieke, MD; Aviv Barzilai, MD, MSc**Phenotypic and Molecular Biomarkers in Cutaneous Lymphomas** | Maarten Vermeer, MD, PhD**D-01 Detection of Multiple Clonal TCR Rearrangements in Cutaneous T-Cell Lymphoma by TCR Clonality by High Throughput Sequencing**

Joseph Cleveland, MD

D-02 High-throughput Sequencing of the T-Cell Receptor β and γ Gene Correlates with Aggressive Subtypes of Mycosis Fungoides and Sézary Syndrome and Immune Checkpoint Expression | Liliana Crisan, MD**D-03 Novel Potential Marker for Sézary Syndrome Diagnosis: TMEM244 Gene** | Karolina Rassek, PhD**D-04 TYK2 Rearranged Primary Cutaneous T-Cell Lymphoma with Novel Presentations** | Melissa Pulitzer, MD**D-05 Progression-associated Genome Alterations in EZH1/2 Revealed by Multi-omic Studies in Cutaneous T-Cell Lymphoma**

Jacqueline Payton, MD, PhD

D-06 Unleashed Monocytic Engagement in Sézary Syndrome During the Combination of Anti-CCR4 Antibody with Type I Interferon

Oleg E. Akilov, MD, PhD

D-07 Integrated Transcriptomics Reveals Cellular and Molecular Interactions in Pruritic Cutaneous T-Cell Lymphoma | Andrea Roggo, MD**D-08 Cellular and Molecular Profiling of Mycosis Fungoides and Primary Cutaneous CD30+ Lymphoproliferative Disorders Reveal Factors Associated with Indolent vs. Aggressive Clinical Behavior** | Katharina Rindler, PhD**D-09 Erythroderma from Cutaneous T-Cell Lymphoma Exhibits a Different Microbial and Proteomic Profile from Erythroderma Caused by Benign Etiologies** | Yanzhen (Janet) Pang, BS**D-10 Single-cell RNA Sequencing of Primary Cutaneous T-Cell Lymphomas with a CD4, CD8 or TCR-gamma/delta Clonal Phenotype Identifies Subset-specific Biomarkers** | Sumanth Chennareddy, BA

6:45 – 7:40 AM	REGISTRATION/BREAKFAST/EXHIBITS/POSTERS BALLROOM DE
7:40 – 7:50 AM	Welcome & Announcements AWARD SESSION: Emilia Hodak, MD ISCL Travel Scholarships & Susan Thornton CLF Young Investigator Award SESSION E TUMOR MICROENVIRONMENT Primary Chair: Christiane Querfeld, MD, PhD Co-Chairs: Neda Nikbakht, MD, PhD; Gabor Dobos, MD, PhD; Florent Amatore, MD, PhD
7:50 – 8:10 AM	The Role of the Tumor Microenvironment Christiane Querfeld, MD, PhD
8:10 – 10:10 AM	E-01 Single Cell Proteomic Analysis Defines a Deferential Exhausted Phenotype in Tumor Microenvironment with Mycosis Fungoides Progression Eleni-Kyriaki Vetsika, BS, PhD E-02 Langerhans Cell Population Expands Early after Immune Checkpoint Inhibition in the Microenvironment of Mycosis Fungoides Duncan Murray, MBChB, PhD E-03 Enhancing Anti-tumor Immunity by Targeting miR-146a and miR-21 in Mycosis Fungoides with Large-cell Transformation Zhen Han, PhD E-04 The Microenvironment in Transformed Mycosis Fungoides: Increased NKG2A and its Role as a Potential Therapeutic Target Pamela Blair Allen, MD, MSc E-05 Recombinant CD155 Promotes Tumor Cell Proliferation as well as IL-13 Expression in Cutaneous T-Cell Lymphoma Ryoma Honda, MD E-06 OX-40 Promotes Tumor Progression in Cutaneous T-Cell Lymphoma by Regulating ERK Activation Evangelia Papadavid, MD, PhD E-07 Total Skin Electron Beam Radiation Therapy is Associated with Enriched Cutaneous Microbial Diversity in Cutaneous T-Cell Lymphoma Madeline J. Hooper, MD E-08 Cutaneous T-Cell Lymphoma Tumors Undergoing Radiation Demonstrate Shifts in Transcriptional Landscape from Malignant Inflammation to Wound Healing and Tissue Remodeling Lauren Chrisman, BA E-09 Differences in the Spatially Resolved Transcriptome Profiles Leading to Progression in Mycosis Fungoides Woo Jin Lee, MD, PhD
10:10 – 10:30 AM	REFRESHMENT BREAK/EXHIBITS/POSTERS
10:30 – 11:05 AM	Primary Chair: Patrick M. Brunner, MD, MSc Co-Chair: Evangelia Papadavid, MD, PhD E-10 M2 Macrophages in the Cutaneous Microenvironment of Mycosis Fungoides and Sézary Syndrome and their Impact on Lymph Node Involvement Daniel Montezzo, MD, PhD E-11 Tumor Promoting Activity of Toll-like Receptor 4 in the Cutaneous T-Cell Lymphoma Microenvironment Neda Nikbakht, MD, PhD E-12 scRNA-Seq Reveals Differential Gene Expression of Cancer-associated Fibroblast Markers in Mycosis Fungoides by Stage and Race Courtney M. Johnson, MD, PhD
11:05 – 11:35 AM	DEBATE: Allogeneic Transplant in Advanced Stage Disease: How Early Should We Do It in the Disease Course? Early vs Late Moderator: Francine M. Foss, MD Swami P. Iyer, MBBS, MD (Early) & Wen-Kai Weng, MD, PhD (Late)
11:35 – 11:45 AM	AWARD SESSION: Emilia Hodak, MD ISCL 2024 Lifetime Achievement Awards
11:45 AM – 12:45 PM	LUNCH/EXHIBITS/POSTERS
12:45 – 1:20 PM	Plenary Lecture Advances & Limitations of CAR T-Cell Therapy L. Elizabeth Budde, MD, PhD SESSION G THERAPEUTICS/PRECLINICAL STUDIES Primary Chair: Michael Khodadoust, MD, PhD Co-Chairs: Ryan A. Wilcox, MD, PhD; Rudolf Stadler, MD, PhD; Jasmine Zain, MD
1:20 – 1:40 PM	The Treatment Landscape of Cutaneous T-Cell Lymphoma: Roadmap Towards Precision Medicine Michael Khodadoust, MD, PhD
1:40 – 2:40 PM	G-01 Durvalumab (Anti-PD-L1) & Lenalidomide is Superior to Single-agent Durvalumab in Refractory/Advanced Cutaneous T-Cell Lymphoma Christiane Querfeld, MD, PhD G-02 Mogamulizumab in combination with Magrolimab (MoMa) in previously treated Mycosis Fungoides and Sézary Syndrome Michael Khodadoust, MD, PhD G-03 PTCL-002 Updates: Pembrolizumab in Combination with Epigenetic Therapy is Safe and Shows Activity in CTCL and PTCL Nathan Roberts, MD G-04 Generation and Optimization of Off-the-Shelf Immunotherapeutics Targeting TCR-Vbeta2+ T Cell Malignancy Michael Girardi, MD G-05 Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Excellent Disease Control in Patients with Refractory/Relapsed Cutaneous Cytotoxic T-Cell Lymphoma Wen-Kai Weng, MD, PhD
2:40 – 3:00 PM	REFRESHMENT BREAK/EXHIBITS/POSTERS
3:00 – 4:00 PM	Primary Chair: H. Miles Prince AM, MBBS (Hons), MD Co-Chairs: Pierluigi Porcu, MD; Richard Cowan, MD; Brad Haverkos, MD; Auris Huen, MD, PharmD G-06 Management of Relapsed Cutaneous T-Cell Lymphoma after Allogeneic Transplantation Wen-Kai Weng, MD, PhD G-07 Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced CTCL: A Single-Centre Experience Including 63 Patients Francesco Onida, MD G-08 Allogeneic Stem Cell Transplant for Treatment of Mycosis Fungoides and Sézary Syndrome: A Systematic Review and Meta-analysis Francine M. Foss, MD G-09 Is Prolonged Treatment with Brentuximab an Alternative? Real-life Experience on Mycosis Fungoides/Sézary Syndrome Patients Jade Cury-Martins, MD, PhD G-10 Methotrexate Single Agent and Combination Treatment in Mycosis Fungoides and Sézary Syndrome. A Multicenter, Retrospective Study Silvia Alberti-Violetti, MD PhD

SESSION F | THERAPEUTICS/PRECLINICAL STUDIES**Primary Chair:** Martine Bagot, MD, PhD | **Co-Chairs:** Wei Ai, MD, PhD; Antonio Cozzio, MD, PhD; Christopher McCormack, MBBS**Identifying Novel Targets for Treatment of Cutaneous T-Cell Lymphoma** | Martine Bagot, MD, PhD

- F-01 **Targeting CDK9 in Cutaneous T-Cell Lymphoma Using Patient-derived Xenograft Models**
Wei Ai, MD, PhD
- F-02 **Targeting the non-ATP-binding Pocket of the MPA Kinase p38 γ Mediates Olfactory Receptor (OR) Directed Cytotoxicity in Cutaneous T-Cell Lymphoma** | Xu Hannah Zhang, PhD
- F-03 **Investigating the Role for DNA Damage Repair (DDR) Pathway Inhibition in Sézary Syndrome**
Farrah Bakr, MBBS, PhD
- F-04 **Comparison of UV-based Combination Therapies for Cutaneous T-Cell Lymphoma Cell Cultures**
Gabor Dobos, MD, PhD
- F-05 **Illuminating Inequities: A Study of Narrowband UVB Therapy Response in Mycosis Fungoides Patients Across Skin Types**
Caroline Chen, BA
- F-06 **Translational Data from a Multicenter Phase II Study on Dimethyl Fumarate Treatment in Relapsed and Refractory Cutaneous T-Cell Lymphoma** | Susanne Melchers, MD
- F-07 **Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Results from the TELLOMAK Phase 2 Trial**
Youn H. Kim, MD
- F-08 **A Phase 2 Study of Low-dose Total Skin Electron Beam Therapy (LD-TSEBT) Combined with Mogamulizumab (TSE-Moga) in Patients with Mycosis Fungoides and Sézary Syndrome** | Ariel Karwat, BSN, MSN-AGNP
- F-09 **Effects of Mogamulizumab on CD39, CD73 and CD38 Ectonucleotidase Expression in CD4+/T Cells in Patients with Sézary Syndrome** | Gabriele Rocuzzo, MD
- F-10 **Assessing the Efficacy of Mogamulizumab of Mycosis Fungoides and Sézary Syndrome Using Time to Next Treatment**
Julia Scarisbrick, MBChB, MD

Primary Chair: Steven M. Horwitz, MD | **Co-Chair:** Steven T. Rosen, MD

- F-11 **RESMAIN: Results of a Multicenter, Randomized, Double Blind, Placebo-controlled Trial to Evaluate RESminostat for MAINTenance Treatment in Advanced Stage Mycosis Fungoides or Sézary Syndrome** | Rudolf Stadler, MD, PhD
- F-12 **Reduced Dose Brentuximab Vedotin for Mycosis Fungoides Appears to Prolong Response Duration by Balancing Efficacy and Tolerability** | Shamir Geller, MD
- F-13 **Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects with Relapsed/Refractory CD30 Positive T-Cell Lymphoma** | Tarsheeh Sethi, MD, MS

KYOWA KIRIN LUNCH SATELLITE SYMPOSIUM | BALLROOM C:**Dodging the Pitfalls of Diagnosing Cutaneous T-Cell Lymphoma (CTCL)** | Alejandro A. Gru, MDUSCLC BOD MTG
BALLROOM A**SESSION H | QUALITY OF LIFE/PATIENT-REPORTED OUTCOMES****Primary Chair:** Kevin Molloy, MB, PhD | **Co-Chairs:** Pamela Blair Allen, MD, MSc; Amy Musiek, MD**Perception of Quality of Life of Patients and Treating Physicians** | Kevin Molloy, MB, PhD

- H-01 **Validation and Psychometric Analysis of the Functional Assessment Cancer Therapy (FACT) – Cutaneous T-Cell Lymphoma**
Christina Asare, BS
- H-02 **First Interim Analysis of a Real-world International Observational Study of Mogamulizumab in Adult Patients with Mycosis Fungoides and Sézary Syndrome (PROSPER study NCT05455931)** | Julia Scarisbrick, MBChB, MD
- H-03 **Patient Perceptions of Multi-disciplinary Teams and Healthcare Expenditure Associated with Cutaneous Lymphomas**
Michael Cao, MBBS
- H-04 **Capturing the Patient Journey Using Electronic Patient-reported Outcome Measures (ePROMs) in Cutaneous B and T-Cell Lymphomas** | Richard Cowan, MD
- H-05 **An Update on Health-related Quality of Life in Mycosis Fungoides/Sézary Syndrome from the PROCLIFI Study**
Kevin Molloy, MB, PhD

Primary Chair: Michi Shinohara, MD | **Co-Chairs:** Constanze Jonak, MD; Ellen J. Kim, MD; Niloufer Khan, MD, MSCE; Cecilia Larocca, MD

- H-06 **Principal Component Analysis and Creation of a Novel Patient-reported Outcomes Questionnaire for Patients with Cutaneous T-Cell Lymphoma** | Neha Akkad, MD
- H-07 **Quality of Life in a Cohort of Asian Children with Mycosis Fungoides**
Mark Jean-Aan Koh, MBBS
- H-08 **A Day in the Life of a Cutaneous Lymphoma Nurse Practitioner at Peter MacCallum Cancer Centre, Melbourne, Australia**
Odette Buelens, BN, MANP-NP
- H-09 **Diagnosis of Cutaneous T-cell Lymphoma in People with Intellectual Disabilities is Delayed**
Brigit A. Lapolla, BS
- H-10 **Interim Analysis Results of an Ongoing Open-label Trial Assessing Silicone-film Forming Wound Dressing as a Steroid-sparing Supportive Therapy for CTCL-induced Pruritus** | Brigit A. Lapolla, BS

EORTC BOD MTG
BALLROOM A

DAY 2 | FRIDAY, APRIL 12, 2024**GENERAL SESSION | BALLROOM F-H**

4:00 – 5:00 PM	G-11 Safety and Tolerability of E7777 (Improved Purity Denileukin Diftitox) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302 H. Miles Prince AM, MBBS (Hons), MD
	G-12 Treatment of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-type (PCDLBCL-LT) in the Modern Era Tarek Bandali, MD
	G-13 Mogamulizumab Combined with Extracorporeal Photopheresis (ECP) as a Novel Therapy in Erythrodermic Cutaneous T-Cell Lymphoma Jan Nicolay, MD, MSc
	G-14 Preliminary Data of Efficacy and Tolerability of Chlormethine Gel with and without Combined Systemic Therapy – A Multicenter Retrospective Study of the German Lymphoma Group Christina Mitteldorf, MD
	G-15 Efficacy and Safety of E7777 (Improved Purity Denileukin Diftitox) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302 Francine M. Foss, MD
5:00 PM	CLOSING REMARKS/ADJOURN DAY 2
6:00 – 7:00 PM	SHUTTLE FROM HOST HOTEL (THE WESTIN PASADENA) TO CONGRESS GALA DINNER <i>Shuttle sponsored by Kyowa Kirin</i>
7:00 – 10:00 PM	CONGRESS GALA DINNER <i>Not included in congress registration. Prepaid Ticket required.</i>
10:00 – 10:30 PM	SHUTTLE FROM CONGRESS GALA DINNER TO HOST HOTEL <i>Shuttle sponsored by Kyowa Kirin</i>

DAY 3 | SATURDAY, APRIL 13, 2024**GENERAL SESSION | BALLROOM F-H**

7:00 – 7:30 AM	REGISTRATION/BREAKFAST/EXHIBITS/POSTERS BALLROOM DE
7:30 – 8:00 AM	ISCL ASSEMBLY MEETING (NON-CME ACCREDITED)
8:00 – 8:05 AM	Welcome & Announcements SESSION I CHALLENGING CASES OF CUTANEOUS LYMPHOMAS <i>Primary Chair:</i> Pietro Quaglino, MD <i>Co-Chairs:</i> Stefan K. Barta, MD, MS ; Iris Amitay-Laish, MD ; Paula Enz, MD
8:05 – 8:25 AM	Facts and Controversies in Cutaneous B-Cell Lymphomas Pietro Quaglino, MD
8:25 – 10:25 AM	I-01 EBV Positive Primary Cutaneous Marginal Zone Lymphoma with Transformation to Plasmablastic Lymphoma Jack Reid, MD
	I-02 Brentuximab Vedotin-associated Tumor Flare Response in a Patient with Mycosis Fungoides with Large Cell Transformation Rishabh Lohray, BS
	I-03 Mogamulizumab-induced Bone Granuloma: A Multicentre Nationwide Case Series Florent Amatore, MD, PhD
	I-04 Pemphigus Foliaceus after Total Skin Electron Beam Radiation for Mycosis Fungoides Leah Cohen, MD
	I-05 Advanced Mycosis Fungoides/Sézary Syndrome Masquerading Atopic Dermatitis in the Era of Advanced Therapeutics – Clues and Pitfalls Iris Amitay-Laish, MD
	I-06 Molecular Genetic Demonstration of the Evolution of Transformed Mycosis Fungoides: A Clinicopathological and Molecular Case Study Melissa Cheng, BS
	I-07 Increased Incidence of Second Primary Malignancies in Patients with Primary Cutaneous B-Cell Lymphomas: A SEER Population Study Henry Yang, BS
	I-08 Bcl6 Expression in a T-Cell Infiltrate...Think Follicular Helper T-Cell Lymphoma Jacqueline M. Junkins-Hopkins, MD
	I-09 Co-expression of CD3 and CD20: A Clue to the Diagnosis of Intestinal Lymphoma Presenting in the Skin Nina Martins, BA
	I-10 Molecularly-annotated Case of a CD30-Positive Gamma-delta T-Cell Features of Primary Cutaneous Anaplastic Large Cell Lymphoma: A Wolf in Sheep's Clothing? Robert E. LeBlanc, MD
	I-11 Hydroa Vacciniforme-like Lymphoproliferative Disorder in a Young Asian Female Ziqi Liu, MD
	I-12 Atypical Presentation of Gamma/Delta (γ/δ) Mycosis Fungoides with an Unusual Phenotype and SOCS1 Mutation Pia Rude Nielsen, MD, PhD
10:25 – 10:45 AM	REFRESHMENT BREAK/EXHIBITS/POSTERS
10:45 – 11:15 AM	DEBATE: Epidermotropic Cutaneous T-Cell Lymphoma with Gamma-delta Phenotype: Is it Mycosis Fungoides or Gamma-delta T-Cell Lymphoma? <i>Moderator:</i> Werner Kempf, MD Alejandro A. Gru, MD (Mycosis Fungoides) & Joan Guitart, MD (Gamma-delta T-Cell Lymphoma)
11:15 – 11:55 AM	Cutaneous T-Cell Lymphoma Jeopardy <i>Moderator:</i> Matt Lunning, DO H. Miles Prince AM, MBBS (Hons), MD & Evangelia Papadavid, MD, PhD Chalid Assaf, MD, PhD & Jasmine Zain, MD Emmanuella Guenova, MD, PhD & Steven M. Horwitz, MD
11:55 AM – 12:35 PM	Best of Congress Youn H. Kim, MD (Therapeutics) & Pablo L. Ortiz-Romero, MD, PhD (Non-Therapeutics)
12:35 PM	CLOSING REMARKS/ADJOURN CONGRESS & LUNCH
1:30 PM	SHUTTLE FROM PASADENA CONVENTION CENTER TO THE HUNTINGTON LIBRARY <i>Shuttle sponsored by CRISPR Therapeutics</i>
2:00 – 5:00 PM	THE HUNTINGTON LIBRARY <i>Not included in congress registration. Pre-registration/Ticket required.</i>
5:15 PM	SHUTTLE FROM THE HUNTINGTON LIBRARY TO PASADENA CONVENTION CENTER <i>Shuttle sponsored by CRISPR Therapeutics</i>

Enhancing the Ability to Diagnose, Interpret and Apply

DAY 2 | FRIDAY, APRIL 12, 2024

BREAKOUT SESSION | BALLROOM B

EORTC BOD MTG
Cont.

Overview of Health Inequity Issues

Kimlin Tam Ashing, PhD
Idoroenyi Amanam, MD

Quality of Life Patient Testimonials

Moderator: Niloufer Khan, MD, MSCE

Briana Castellanos
Michaeldiamond E. McGee
Joseph Odundo Okeyo

DAY 3 | SATURDAY, APRIL 13, 2024

BREAKOUT SESSION | BALLROOM B

SESSION J | LEADING-EDGE RESEARCH AND FUTURE DIRECTIONS OF CUTANEOUS LYMPHOMAS

Primary Chair: Oleg E. Akilov, MD, PhD

Co-Chairs: Yang Wang, MD; Sima Rozati, MD, PhD; Makoto Sugaya, MD, PhD

Multiomics in Cutaneous T-Cell Lymphoma | Oleg E. Akilov, MD, PhD

- J-01 Utilising 3D Images for the Virtual Assessment of Patients with Cutaneous T-Cell Lymphoma**
Jillian Wells, MBBS (Hons)
- J-02 WEKAnalysis: Machine Learning and Database Analysis for Classification of CTCL Patients versus Controls**
Emily R. Gordon, BA
- J-03 Innovative Identification of Sézary Cells: A Transcriptome-based Approach to Clonal Variability and Distinct Phenotypes**
Oleg E. Akilov, MD, PhD
- J-04 Computational Free Flow Cytometry for Sézary Cells Identification and Quantification** | Hélène Moins, MD, PhD
- J-05 Leveraging Deep Learning to Resolve Skin Lymphoma Using Highly Multiplexed Protein Fluorescent Imaging**
Pacôme Prompsy
- J-06 Hemophagocytic Lymphohistiocytosis Machine Learning Prediction in Subcutaneous Panniculitis-like T-Cell Lymphoma**
Tho Ngoc-Quynh Le, MD
- J-07 Identification of Distinct Gene Expression Profiles from Mycosis Fungoides Atopic Dermatitis, and Psoriasis Lesions Using a Non-invasive Skin Sampling Technique** | Heather W. Goff, MD
- J-08 Gut Microbiome of Cutaneous T-Cell Lymphoma Patients is Altered Following Narrowband Ultraviolet-B Phototherapy and Exhibits Profiles that Predict Treatment Responsiveness** | William Nguyen, BS
- J-09 T-Cell Receptor High-throughput Sequencing and TRBC1 Immunohistochemistry in the Evaluation of Persistent Cutaneous T-Cell Lymphoma in Mogamulizumab-associated Rash** | Andrea P. Moy, MD

Best Treatment Options for Cutaneous Lymphomas

